Munich - Delayed Quote EUR

Aadi Bioscience Inc (3350.MU)

1.3700
0.0000
(0.00%)
As of 8:04:57 AM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
25,983
25,983
24,354
15,216
1,000
Cost of Revenue
3,024
3,024
2,809
1,335
--
Gross Profit
22,959
22,959
21,545
13,881
1,000
Operating Expense
87,779
87,779
93,478
72,838
38,061
Operating Income
-64,820
-64,820
-71,933
-58,957
-37,061
Net Non Operating Interest Income Expense
3,771
3,771
6,169
2,168
-652
Other Income Expense
-2,642
-2,642
-1
-3,724
-72,375
Pretax Income
-63,691
-63,691
-65,765
-60,513
-110,088
Tax Provision
--
--
--
--
2
Net Income Common Stockholders
-63,691
-63,691
-65,765
-60,513
-110,737
Diluted NI Available to Com Stockholders
-63,691
-63,691
-65,765
-60,513
-110,737
Basic EPS
-2.28
-2.36
-2.44
-2.69
-12.41
Diluted EPS
-2.28
-2.36
-2.44
-2.69
-12.41
Basic Average Shares
26,999.7030
27,029.9420
26,917.9670
22,511.2370
8,923.3690
Diluted Average Shares
26,999.7030
27,029.9420
26,917.9670
22,511.2370
8,923.3690
Total Operating Income as Reported
-67,458
-67,458
-71,933
-62,681
-111,217
Total Expenses
90,803
90,803
96,287
74,173
38,061
Net Income from Continuing & Discontinued Operation
-63,691
-63,691
-65,765
-60,513
-110,090
Normalized Income
-61,049
-61,049
-65,764
-56,789
-56,099.2000
Interest Income
3,925
3,925
6,400
2,398
13
Interest Expense
154
154
231
230
665
Net Interest Income
3,771
3,771
6,169
2,168
-652
EBIT
-63,537
-63,537
-65,534
-60,283
-109,423
EBITDA
-63,344
-63,344
-65,365
-60,124
-109,318
Reconciled Cost of Revenue
3,024
3,024
2,809
1,335
--
Reconciled Depreciation
193
193
169
159
105
Net Income from Continuing Operation Net Minority Interest
-63,691
-63,691
-65,765
-60,513
-110,090
Total Unusual Items Excluding Goodwill
-2,642
-2,642
-1
-3,724
-73,960
Total Unusual Items
-2,642
-2,642
-1
-3,724
-73,960
Normalized EBITDA
-60,702
-60,702
-65,364
-56,400
-35,358
Tax Rate for Calcs
--
--
--
--
0.0003
Tax Effect of Unusual Items
--
--
--
--
-19,969.2000
12/31/2021 - 9/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade